Paris, France, April 4, 2023, 5:45 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announces that its management team will host a live webcast on Wednesday, April 5, 2023, to provide update on LUMEVOQ® manufacturing issues encountered in March, following investigations findings at the Company’s manufacturing partner in the United-States. GenSight confirms the start of the validation campaign in May 2023, with results expected in Q3 2023, as previously announced.
The webcast will be held in English, and a simultaneous French translation will also be available.
- Wednesday April 5, 2023
- 8:00 EST / 2:00 pm CEST
- Live webcast in English, with a simultaneous French translation also available: GenSight Biologics Manufacturing Update Webcast (royalcast.com)
The webcast will be available in replay using the same link above.
GenSight BiologicsCorporate Communications DirectorClothilde Caillet
Rooney PartnersMedia RelationsJeanene Timberlake+1 646-770-8858
LifeSci AdvisorsInvestor RelationsGuillaume van Renterghem+41 (0)76 735 01 31
Orpheon FinanceRetail InvestorsJames Palmer+33 7 60 92 77 74